Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Ascendis Pharma A/S is a biotechnology business based in the US. Ascendis Pharma A/S shares (ASND) are listed on the NASDAQ and all prices are listed in US Dollars. Ascendis Pharma A/S employs 330 staff and has a market cap (total outstanding shares value) of USD$8.2 billion.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$92 - USD$183.98 |
---|---|
50-day moving average | USD$158.5229 |
200-day moving average | USD$157.794 |
Wall St. target price | USD$193.26 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-5.0945 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$13.4 million |
---|---|
Return on assets TTM | -21.04% |
Return on equity TTM | -44.69% |
Profit margin | 0% |
Book value | $8.431 |
Market capitalisation | USD$8.2 billion |
TTM: trailing 12 months
There are currently 2.1 million Ascendis Pharma A/S shares held short by investors – that's known as Ascendis Pharma A/S's "short interest". This figure is 1% down from 2.2 million last month.
There are a few different ways that this level of interest in shorting Ascendis Pharma A/S shares can be evaluated.
Ascendis Pharma A/S's "short interest ratio" (SIR) is the quantity of Ascendis Pharma A/S shares currently shorted divided by the average quantity of Ascendis Pharma A/S shares traded daily (recently around 152554.2591267). Ascendis Pharma A/S's SIR currently stands at 13.97. In other words for every 100,000 Ascendis Pharma A/S shares traded daily on the market, roughly 13970 shares are currently held short.
However Ascendis Pharma A/S's short interest can also be evaluated against the total number of Ascendis Pharma A/S shares, or, against the total number of tradable Ascendis Pharma A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ascendis Pharma A/S's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Ascendis Pharma A/S shares in existence, roughly 40 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Ascendis Pharma A/S shares, roughly 0 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Ascendis Pharma A/S.
Find out more about how you can short Ascendis Pharma A/S stock.
We're not expecting Ascendis Pharma A/S to pay a dividend over the next 12 months.
Over the last 12 months, Ascendis Pharma A/S's shares have ranged in value from as little as $92 up to $183.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ascendis Pharma A/S's is 0.7978. This would suggest that Ascendis Pharma A/S's shares are less volatile than average (for this exchange).
Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.